AR060018A1 - Emulsion termorreversible de aceite en agua - Google Patents
Emulsion termorreversible de aceite en aguaInfo
- Publication number
- AR060018A1 AR060018A1 ARP070100152A ARP070100152A AR060018A1 AR 060018 A1 AR060018 A1 AR 060018A1 AR P070100152 A ARP070100152 A AR P070100152A AR P070100152 A ARP070100152 A AR P070100152A AR 060018 A1 AR060018 A1 AR 060018A1
- Authority
- AR
- Argentina
- Prior art keywords
- water
- oil emulsion
- thermal reversible
- reversible oil
- emulsion
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 title 1
- 230000002441 reversible effect Effects 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicacion 1: Una emulsion de aceite en agua (O/W) que comprende: i) un agonista de TLR4, denominado TLA4, la estructura química del cual no comprende un anillo de azucar. ii ) escualeno, iii) un solvente acuoso, iv) un tensioactivo hidrofilo no ionico que es un éter alquílico de polioxietileno, v) un tensioactivo hidrofobo no ionico y que es termorreversible.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0600309A FR2896162B1 (fr) | 2006-01-13 | 2006-01-13 | Emulsion huile dans eau thermoreversible |
Publications (1)
Publication Number | Publication Date |
---|---|
AR060018A1 true AR060018A1 (es) | 2008-05-21 |
Family
ID=37103105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100152A AR060018A1 (es) | 2006-01-13 | 2007-01-12 | Emulsion termorreversible de aceite en agua |
Country Status (14)
Country | Link |
---|---|
US (1) | US9504659B2 (es) |
EP (1) | EP1976560B1 (es) |
JP (1) | JP5226534B2 (es) |
KR (1) | KR20080091808A (es) |
CN (2) | CN105709223A (es) |
AR (1) | AR060018A1 (es) |
AU (1) | AU2007204295B2 (es) |
BR (1) | BRPI0706527A2 (es) |
CA (1) | CA2635724A1 (es) |
FR (1) | FR2896162B1 (es) |
IL (1) | IL192475A (es) |
MX (1) | MX2008009024A (es) |
WO (1) | WO2007080308A2 (es) |
ZA (1) | ZA200805651B (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
WO2006100111A1 (en) | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Composition |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
CN101679974B (zh) | 2007-03-27 | 2015-09-30 | 航道生物技术有限责任公司 | 包含抗体替代轻链序列的构建体和文库 |
US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
EP3459563A1 (en) | 2008-03-18 | 2019-03-27 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
CA2719201A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc. | Neutralizing molecules to viral antigens |
JP4938911B2 (ja) | 2008-08-28 | 2012-05-23 | ノバルティス アーゲー | 高度に生産する酵母からのスクアレンの生産 |
KR20110061611A (ko) | 2008-09-18 | 2011-06-09 | 노파르티스 아게 | 백신 보조제 조합 |
EA201171032A1 (ru) | 2009-02-10 | 2012-02-28 | Новартис Аг | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
CN105727281A (zh) | 2009-02-10 | 2016-07-06 | 诺华股份有限公司 | 具有减少量的角鲨烯的流感疫苗 |
MX338898B (es) * | 2009-02-17 | 2016-05-03 | Glaxosmithkline Biolog Sa | Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio. |
MX363222B (es) | 2009-04-14 | 2019-03-15 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
AU2010250832B2 (en) | 2009-05-21 | 2013-10-03 | Seqirus UK Limited | Reverse genetics using non-endogenous pol I promoters |
CN102666860B (zh) | 2009-07-31 | 2015-06-17 | 诺华股份有限公司 | 反向遗传系统 |
US20110052633A1 (en) * | 2009-09-02 | 2011-03-03 | National Health Research Institutes | Multi-phase emulsions based on amphiphilic block copolymers |
PL2491117T3 (pl) | 2009-10-20 | 2014-05-30 | Novartis Ag | Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP5751678B2 (ja) | 2009-12-03 | 2015-07-22 | ノバルティス アーゲー | マイクロフルイダイゼーションのための相互作用チャンバおよび背圧チャンバの構成 |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
SI2356983T1 (sl) | 2009-12-03 | 2013-05-31 | Novartis Ag | KroĹľenje komponent med homogenizacijo emulzij |
DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
CN104688687A (zh) | 2009-12-03 | 2015-06-10 | 诺华股份有限公司 | 疫苗佐剂制备中的亲水过滤 |
EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
US9199897B2 (en) | 2010-05-12 | 2015-12-01 | Novartis Ag | Methods for preparing squalene |
EP2571520B1 (en) | 2010-05-21 | 2018-04-04 | Seqirus UK Limited | Influenza virus reassortment method |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
MX2013006255A (es) | 2010-12-03 | 2015-08-05 | Sanofi Pasteur Ltd | Composicion para inmunizacion contra streptococcus pneumoniae. |
WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
ES2785108T3 (es) | 2011-03-24 | 2020-10-05 | Glaxosmithkline Biologicals Sa | Nanoemulsiones adyuvantes con fosfolípidos |
WO2013016714A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
WO2013043580A2 (en) | 2011-09-19 | 2013-03-28 | Gencia Corporation | Modified creatine compounds |
JP2014532620A (ja) | 2011-10-20 | 2014-12-08 | ノバルティス アーゲー | 小児の初回免疫のためのアジュバント添加インフルエンザbウイルスワクチン |
ES2710916T3 (es) | 2011-12-22 | 2019-04-29 | I2 Pharmaceuticals Inc | Proteínas de unión sustitutas |
JP2015500864A (ja) | 2011-12-23 | 2015-01-08 | ノバルティス アーゲー | 黄色ブドウ球菌(Staphylococcusaureus)に対して免疫するための安定な組成物 |
HUE044841T2 (hu) * | 2012-02-07 | 2019-11-28 | Infectious Disease Res Inst | TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai |
US9708562B2 (en) * | 2012-02-10 | 2017-07-18 | Soane Energy, Llc | Rapidly inverting water-in-oil polymer emulsions |
ES2628301T3 (es) | 2012-03-02 | 2017-08-02 | Seqirus UK Limited | Recombinación de virus de gripe |
US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
WO2013184900A2 (en) | 2012-06-06 | 2013-12-12 | Sanofi Pasteur Biologics, Llc | Immunogenic compositions and related methods |
BR112015001313A2 (pt) | 2012-07-24 | 2017-08-01 | Sanofi Pasteur | composições de vacina |
MY197723A (en) | 2012-07-24 | 2023-07-10 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
US20150203543A1 (en) | 2012-08-31 | 2015-07-23 | Novartis Ag | Stabilised proteins for immunising against staphylococcus aureus |
JP6435261B2 (ja) | 2012-08-31 | 2018-12-05 | ノバルティス アーゲー | Staphylococcusaureusに対する免疫化のための安定化されたタンパク質 |
MX2015002717A (es) | 2012-09-06 | 2015-05-15 | Novartis Ag | Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina. |
CA2886938A1 (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
EP3345617B1 (en) | 2012-11-30 | 2020-08-26 | GlaxoSmithKline Biologicals S.A. | Pseudomonas antigens and antigen combinations |
WO2014083194A1 (en) | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
AU2013354219A1 (en) | 2012-12-03 | 2015-07-02 | Novartis Ag | Reassortant influenza a viren |
CA2894260A1 (en) | 2012-12-18 | 2014-06-26 | Glaxosmithkline Biologicals S.A. | Conjugates for protecting against diphtheria and/or tetanus |
JP6525469B2 (ja) | 2013-03-13 | 2019-06-05 | ノバルティス アーゲー | インフルエンザb型ウイルス再集合 |
CN105828835A (zh) | 2013-05-10 | 2016-08-03 | 诺华股份有限公司 | 避免流感疫苗中的发作性嗜睡病风险 |
DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
EP3004332A2 (en) | 2013-06-06 | 2016-04-13 | Novartis AG | Influenza virus reassortment |
CN109893648A (zh) | 2013-06-28 | 2019-06-18 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
AU2014373928C1 (en) * | 2013-12-31 | 2020-12-17 | Access To Advanced Health Institute | Single vial vaccine formulations |
US10328140B2 (en) | 2014-03-26 | 2019-06-25 | Glaxosmithkline Biologicals S.A. | Mutant staphylococcal antigens |
WO2015200381A1 (en) * | 2014-06-23 | 2015-12-30 | Massachusetts Institute Of Technology | Emulsions by condensation |
BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
CN108367062B (zh) | 2015-10-13 | 2022-05-06 | 赛诺菲巴斯德有限公司 | 抗金黄色葡萄球菌的免疫原性组合物 |
US9872832B2 (en) * | 2015-10-23 | 2018-01-23 | LG Bionano, LLC | Nanoemulsions having reversible continuous and dispersed phases |
JP6559898B2 (ja) * | 2015-12-16 | 2019-08-14 | ヒュヴェット・バイオ・インコーポレイテッド | スクアレンを含む両親媒性ポリアミノ酸高分子に基づくワクチンの免疫補助剤組成物 |
WO2017137085A1 (en) | 2016-02-11 | 2017-08-17 | Sanofi Pasteur | Meningitidis vaccines comprising subtilinases |
CN108884020A (zh) | 2016-02-26 | 2018-11-23 | 奥克兰联合服务有限公司 | 氨基酸及肽共轭物以及共轭过程 |
JP6992057B2 (ja) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法 |
US11524069B2 (en) | 2017-09-13 | 2022-12-13 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
CN108159414B (zh) * | 2018-01-15 | 2021-07-27 | 四川诺顺科技有限公司 | 动物疫苗用油包水佐剂及其制备方法和用途 |
US20230000971A1 (en) | 2019-11-18 | 2023-01-05 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
US20230218526A1 (en) | 2020-06-30 | 2023-07-13 | Seqirus UK Limited | Cold filtration of oil-in-water emulsion adjuvants |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
WO1990014837A1 (en) * | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
US5718904A (en) * | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
US5744062A (en) * | 1996-08-29 | 1998-04-28 | R.I.T.A. Corporation | Balanced emulsifier blends for oil-in-water emulsions |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
IL145982A0 (en) * | 1999-04-19 | 2002-07-25 | Smithkline Beecham Biolog | Vaccines |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
DE10025671B4 (de) * | 2000-05-24 | 2006-07-27 | Cognis Ip Management Gmbh | Emulgatoren |
CA2511512C (en) * | 2002-12-27 | 2013-10-29 | Chiron Corporation | Immunogenic compositions containing phospholipid |
DE10318310A1 (de) * | 2003-04-14 | 2004-11-25 | Xaver Lipp | Vorrichtung zum Öffnen eines Ventils, insbesondere eines Lufteinlaßventils oder Gasauslaßventils eines Gär-oder Faulbehälters |
EP1651265B1 (en) * | 2003-07-24 | 2008-04-23 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
US20050023729A1 (en) * | 2003-07-31 | 2005-02-03 | Smith Leslie E. | Formation of wide paint film parts |
DE10337451A1 (de) | 2003-08-14 | 2005-03-17 | Cognis Deutschland Gmbh & Co. Kg | Verwendung von PIT-Emulsionen in enzymatischen Reaktionen |
WO2006100111A1 (en) * | 2005-03-23 | 2006-09-28 | Glaxosmithkline Biologicals S.A. | Composition |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US20070292418A1 (en) * | 2005-04-26 | 2007-12-20 | Eisai Co., Ltd. | Compositions and methods for immunotherapy |
US8703095B2 (en) * | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
EP2377552A3 (en) | 2005-11-04 | 2013-05-15 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines with reduced amount of emulsion adjuvant |
JP2009514839A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | サイトカイン誘導剤を含むアジュバントインフルエンザワクチン |
-
2006
- 2006-01-13 FR FR0600309A patent/FR2896162B1/fr active Active
-
2007
- 2007-01-09 MX MX2008009024A patent/MX2008009024A/es active IP Right Grant
- 2007-01-09 EP EP07717813.5A patent/EP1976560B1/fr active Active
- 2007-01-09 KR KR1020087019806A patent/KR20080091808A/ko active Search and Examination
- 2007-01-09 AU AU2007204295A patent/AU2007204295B2/en not_active Ceased
- 2007-01-09 CN CN201510951842.XA patent/CN105709223A/zh active Pending
- 2007-01-09 JP JP2008549901A patent/JP5226534B2/ja active Active
- 2007-01-09 CA CA002635724A patent/CA2635724A1/en not_active Abandoned
- 2007-01-09 ZA ZA200805651A patent/ZA200805651B/xx unknown
- 2007-01-09 BR BRPI0706527-2A patent/BRPI0706527A2/pt not_active IP Right Cessation
- 2007-01-09 WO PCT/FR2007/000030 patent/WO2007080308A2/fr active Application Filing
- 2007-01-09 CN CN200780003005A patent/CN101636178A/zh active Pending
- 2007-01-10 US US11/621,860 patent/US9504659B2/en active Active
- 2007-01-12 AR ARP070100152A patent/AR060018A1/es unknown
-
2008
- 2008-06-26 IL IL192475A patent/IL192475A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1976560B1 (fr) | 2014-01-08 |
AU2007204295B2 (en) | 2012-11-22 |
FR2896162A1 (fr) | 2007-07-20 |
AU2007204295A1 (en) | 2007-07-19 |
JP2009523158A (ja) | 2009-06-18 |
KR20080091808A (ko) | 2008-10-14 |
WO2007080308A2 (fr) | 2007-07-19 |
ZA200805651B (en) | 2010-07-28 |
JP5226534B2 (ja) | 2013-07-03 |
MX2008009024A (es) | 2009-03-05 |
FR2896162B1 (fr) | 2008-02-15 |
CN105709223A (zh) | 2016-06-29 |
US20070191314A1 (en) | 2007-08-16 |
CN101636178A (zh) | 2010-01-27 |
CA2635724A1 (en) | 2007-07-19 |
WO2007080308A3 (fr) | 2009-09-24 |
BRPI0706527A2 (pt) | 2011-03-29 |
US9504659B2 (en) | 2016-11-29 |
EP1976560A2 (fr) | 2008-10-08 |
IL192475A0 (en) | 2009-08-03 |
IL192475A (en) | 2014-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR060018A1 (es) | Emulsion termorreversible de aceite en agua | |
AR121096A2 (es) | Formulaciones de vacunas que comprenden adyuvantes con saponina | |
UA94404C2 (ru) | Новые композиции вакцин | |
ES2585810T3 (es) | Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada | |
ES2525238T3 (es) | Método para preparar emulsiones aceite-en-agua a partir de concentrados de geles autoemulsionantes | |
AR073457A1 (es) | Fluidos de dioxido de cloro no citotoxico, composicion oxidante de irritacion reducida | |
AR056808A1 (es) | Formulacion de aceite en agua de avermectinas | |
PE20050775A1 (es) | Formulaciones que comprenden multiparticulas de liberacion controlada | |
EA201290584A1 (ru) | Сжимаемые пакерные жидкости, а также способы их получения и применения | |
CR8814A (es) | Composiciones plaguicidas liquidas | |
EA200801250A1 (ru) | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа | |
ECSP088668A (es) | Sistema de administracion de plaguicidas | |
CL2011000767A1 (es) | Emulsion de aceite en agua que contiene (i) fase hidrofobica interna en cantidades desde 1 a 40 %, (ii)una fase hidrofilica externa desde 60 a 99 %, (iii) al menos un surfactante polimerico en cantidades desde 0,50 a 2,50 y (iv) al menos unprincipio activo insoluble en agua en cantidades desde 0,01 al 25 % por peso. | |
ATE365538T1 (de) | O/w emulsion | |
AR071568A1 (es) | Composicion de suspension pesticida acuosa | |
WO2007069214A3 (en) | Wet wipes with natural antimicrobial agents | |
IL210354A0 (en) | Oil - in - water emulsion comprising solvent, water, surfactant and pesticide | |
GT200600405A (es) | Formula de microemulsión | |
AR055758A1 (es) | Tanque para dispositivo optico para analisis de sangre, aparato de analisis equipado con tal tanque | |
RU2014115278A (ru) | Косметическая эмульсия типа "масло в воде" | |
ES2605440T3 (es) | Emulsiones estabilizadas con micelas de proteínas de suero de leche | |
TW200637579A (en) | Solid composition comprising oil-in-water type emulsion | |
AR059676A1 (es) | Cassette quirurjico con estructura rompedora de burbuja | |
WO2008013669A3 (en) | Alpha hydroxy acid sustained release formulation | |
AR044167A1 (es) | Sistemas homogeneos a base de sacarido liquido y aceite |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |